Synthetic Cell Surface Receptors for Anticancer Drug Delivery
Synthetic Cell Surface Receptors for Anticancer Drug Delivery
批准号:
7842667
负责人:
BLAKE PETERSON
金额:
$24.39万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-01-01 至 2011-04-30
关键词:
Active Biological TransportAffinityAnimalsAntineoplastic AgentsBindingBiochemicalBiologicalBiological AssayCell Culture TechniquesCell Surface ReceptorsCell membraneCell surfaceCellsCellular MembraneCholesterolCholesterol HomeostasisCleaved cellComplexConfocal MicroscopyDataDisseminated Malignant NeoplasmDisulfidesDoxorubicinDrug Delivery SystemsDrug KineticsEndocytosisEndosomesEnvironmentEnzymesExhibitsGelatinase AGrantHalf-LifeHealthHigh Density LipoproteinsHumanHydroxylationIn VitroIronLifeLigandsLinkLipoproteinsLow-Density LipoproteinsMammalian CellMatrix MetalloproteinasesMediatingMediator of activation proteinMembraneMembrane Protein TrafficMetabolicMetabolismMethodsModelingMolecular ProbesNatureNormal CellNutrientPathway interactionsPeptide HydrolasesPeptidesPharmaceutical PreparationsPlasmaProblem SolvingPropertyProtein OverexpressionRNA InterferenceRecyclingResearchSerumSpecificityStructureSystemTimeTissuesToxic effectTransferrinTransferrin ReceptorTransferrin-Binding ProteinsVertebratesbasecancer cellcell typecholesterylaminedesignextracellularimprovedin vivoinnovationneoplastic cellnovelnovel strategiesoverexpressionparticlepublic health relevancereceptortooltraffickingtumoruptake
中文摘要
描述(由申请人提供):药物递送中未解决的主要问题之一是如何将渗透性差的分子转运穿过膜屏障。自然界解决这个问题的方式是通过膜运输;细胞不可渗透的配体,如携带铁的转铁蛋白结合同源受体,在这种情况下,转铁蛋白受体,驻留在动态膜运输途径。转铁蛋白受体所占据的途径涉及细胞表面和早期/再循环内体之间的快速循环,将转铁蛋白递送至脊椎动物的每个细胞,并且代表显著的天然递送载体。在最后一个赠款周期,我们证明了衍生物的合成膜锚N-烷基-3?-胆固醇胺表现出独特的生物活性:当添加到哺乳动物细胞中时,它们有效地参与由转铁蛋白受体占据的膜运输途径,并在质膜和早期/再循环内体之间快速循环。这样,N-烷基-3?胆固醇胺可以作为小的人工细胞表面受体;当与药物结合基序连接时,它们可以通过内吞作用将药物运送到细胞和组织中。这些化合物似乎在功能上模拟游离胆固醇,游离胆固醇是血浆和内体膜的关键组分。它们结合胆固醇负载的LDL和HDL颗粒,并可能参与天然胆固醇的摄取和运输机制。由于转铁蛋白受体介导的转铁蛋白的递送是如此有效,胆固醇胺有效地参与相同的膜运输途径的能力提供了前所未有的潜力,以创造用于药物递送的变革性新工具。这一建议的重点是阐明机制,控制独特的生物活性的N-烷基-3?胆固醇胺通过合成和评价一组化合物的生物学特性,这些化合物在靠近该膜锚的连接区具有结构多样性,我们将获得定量结构-特性关系(QSPR),其设计用于预测细胞摄取、运输、流出、代谢和毒性特性。结构相关的光交联剂,RNAi方法和蛋白质过表达将用于识别参与细胞摄取和流出的受体和配体。这些生物活性的介质将对N-烷基-3,3-二氢吡喃的药代动力学产生深远的影响。体内胆固醇胺。我们进一步建议构建第一个抗癌药物递送系统,旨在通过访问一个定义的膜运输途径跨越膜屏障。为了获得对转移性癌细胞超过正常细胞的特异性,肿瘤特异性蛋白酶的肽底物将用于将胆固醇胺连接到抗癌药物阿霉素。当被转移性癌细胞表达的MMP-2蛋白酶切割时,这种药物将选择性地释放。我们将优化阿霉素和相关分子探针在体外向癌细胞的递送,以验证一个全新的概念:参与确定的膜运输途径的化合物为选择性递送抗癌药物提供了一种新的策略。公共卫生相关性:这里提出的研究与人类健康的进步高度相关。在过去的格兰特周期中,我们发现了被称为N-烷基-3?胆固醇胺参与由转铁蛋白受体占据的特异性膜运输途径。这种生物活性使这些化合物能够在哺乳动物细胞中定义跨膜屏障的新途径。通过阐明这些化合物的生物学机制,我们建议创建创新的抗癌药物递送新工具。
英文摘要
DESCRIPTION (provided by applicant): One of the major unsolved problems in drug delivery is how to transport poorly permeable molecules across membrane barriers. The way that Nature solves this problem is through membrane trafficking; cell impermeable ligands such as the iron-carrying transferrin protein bind cognate receptors, in this case the transferrin receptor, that reside in dynamic membrane trafficking pathways. The pathway occupied by the transferrin receptor involves rapid cycling between the cell surface and early/recycling endosomes, delivers transferrin to every cell of vertebrate animals, and represents a remarkable natural delivery vehicle. In the last grant cycle, we demonstrated that derivatives of the synthetic membrane anchor N-alkyl-3?-cholesterylamine exhibit a unique biological activity: when added to mammalian cells, they efficiently engage the membrane trafficking pathway occupied by the transferrin receptor and rapidly cycle between the plasma membrane and early/recycling endosomes. In this way, N-alkyl-3?-cholesterylamines can function as small artificial cell surface receptors; when linked to drug-binding motifs, they can shuttle drugs into cells and tissues via endocytosis. These compounds appear to functionally mimic free cholesterol, a key component of plasma and endosomal membranes. They bind cholesterol-laden LDL and HDL particles and presumably participate in natural cholesterol uptake and trafficking mechanisms. Because delivery of transferrin mediated by the transferrin receptor is so efficient, the ability of cholesterylamines to efficiently engage the same membrane trafficking pathway offers unprecedented potential to create transformative new tools for drug delivery. This proposal is focused on elucidating mechanisms that control the unique biological activities of N-alkyl-3?-cholesterylamines. By synthesizing and evaluating the biological properties of a panel of compounds bearing structural diversity in the linker region proximal to this membrane anchor, we will obtain quantitative structure-property relationships (QSPR) designed to predict cellular uptake, trafficking, efflux, metabolism, and toxicity properties. Structurally related photocrosslinkers, RNAi methods, and protein overexpression will be used to identify receptors and ligands involved in cellular uptake and efflux. These mediators of biological activity will have a profound effect on the pharmacokinetics of N-alkyl-3?-cholesterylamines in vivo. We further propose to construct the first anticancer drug delivery systems designed to cross membrane barriers by accessing a defined membrane trafficking pathway. To gain specificity for metastatic cancer cells over normal cells, peptide substrates of tumor-specific proteases will be used to link cholesterylamines to the anticancer drug doxorubicin. This drug will be selectively released when cleaved by the MMP-2 protease expressed by metastatic cancer cells. We will optimize the delivery of doxorubicin and related molecular probes into cancer cells in vitro to validate a fundamentally new concept: compounds that engage a defined membrane trafficking pathway offer a new strategy for the selective delivery of anticancer agents. PUBLIC HEALTH RELEVANCE: The research proposed here is highly relevant to the advancement of human health. In the past grant cycle we discovered that synthetic compounds termed N-alkyl-3?-cholesterylamines engage the specific membrane trafficking pathway occupied by the transferrin receptor. This biological activity enables these compounds to define new pathways across membrane barriers in mammalian cells. By elucidating biological mechanisms of these compounds, we propose to create innovative new tools for anticancer drug delivery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic Lethal Targeting of Growth Factor Receptors
-
批准号:9218305
-
项目类别:
-
资助金额:$32.91万
-
财政年份:2017
-
负责人:BLAKE PETERSON
-
依托单位:
Synthetic Lethal Targeting of Growth Factor Receptors
-
批准号:10065292
-
项目类别:
-
资助金额:$35.69万
-
财政年份:2017
-
负责人:BLAKE PETERSON
-
依托单位:
Synthetic Chemical Biology
-
批准号:10245047
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2012
-
负责人:BLAKE PETERSON
-
依托单位:
Tissue-specific delivery of probes by control of membrane trafficking of endoprot
-
批准号:7817256
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:BLAKE PETERSON
-
依托单位:
Tissue-specific delivery of probes by control of membrane trafficking of endoprot
-
批准号:7937894
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:BLAKE PETERSON
-
依托单位:
University of Kansas/Haskell Indian Nations University IRACDA Project
-
批准号:8708099
-
项目类别:
-
资助金额:$33.04万
-
财政年份:2002
-
负责人:BLAKE PETERSON
-
依托单位:
University of Kansas/Haskell Indian Nations University IRACDA Project
-
批准号:8367984
-
项目类别:
-
资助金额:$48.65万
-
财政年份:2002
-
负责人:BLAKE PETERSON
-
依托单位:
University of Kansas/Haskell Indian Nations University IRACDA Project
-
批准号:9527924
-
项目类别:
-
资助金额:$15.98万
-
财政年份:2002
-
负责人:BLAKE PETERSON
-
依托单位:
University of Kansas/Haskell Indian Nations University IRACDA Project
-
批准号:8516517
-
项目类别:
-
资助金额:$51.88万
-
财政年份:2002
-
负责人:BLAKE PETERSON
-
依托单位:
University of Kansas/Haskell Indian Nations University IRACDA Project
-
批准号:8898829
-
项目类别:
-
资助金额:$51.85万
-
财政年份:2002
-
负责人:BLAKE PETERSON
-
依托单位:
RECEPTOR MEMBRANE ANCHORING WITH SYNTHETIC ANTIESTROGENS
-
批准号:6489325
-
项目类别:
-
资助金额:$16.94万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Cancer Therapeutics that Anchor Proteins to Membranes
-
批准号:6697523
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
RECEPTOR MEMBRANE ANCHORING WITH SYNTHETIC ANTIESTROGENS
-
批准号:6027869
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Cancer Therapeutics that Anchor Proteins to Membranes
-
批准号:6991318
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Synthetic Cell Surface Receptors for Anticancer Drug Delivery
-
批准号:7730812
-
项目类别:
-
资助金额:$24.31万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Synthetic Cell Surface Receptors for Anticancer Drug Delivery
-
批准号:8193087
-
项目类别:
-
资助金额:$23.67万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
RECEPTOR MEMBRANE ANCHORING WITH SYNTHETIC ANTIESTROGENS
-
批准号:6342185
-
项目类别:
-
资助金额:$16.44万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Cancer Therapeutics that Anchor Proteins to Membranes
-
批准号:6580126
-
项目类别:
-
资助金额:$22.74万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Cancer Therapeutics that Anchor Proteins to Membranes
-
批准号:6832201
-
项目类别:
-
资助金额:$24.5万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
Cancer Therapeutics that Anchor Proteins to Membranes
-
批准号:7172627
-
项目类别:
-
资助金额:$23.19万
-
财政年份:2000
-
负责人:BLAKE PETERSON
-
依托单位:
海外基金